GerkOne said I wasn't expecting to hit the kinds of numbers I did right away but I am glad that the record exceeded my expectations because it has just motivated
Results from a Phase 2 trial of Covaxin indicate that it is safe and well tolerated, while unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease.